Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Resolve Therapeutics, LLC
--Novel Biologic Targets Innovative New Mechanism in Lupus--
SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month phase 2 clinical study with its lead compound RSLV-132 in systemic lupus erythematosus (SLE).
Following the successful completion of it phase 1 single dose safety study with RSLV-132, Resolve recently initiated a phase 2 study in lupus patients. The study will be conducted at multiple sites in the U.S., and will investigate four dose levels, with multiple doses being administered over one month. The study is designed to establish biological proof-of-concept for RSLV-132.
RSLV-132 is a novel Fc fusion protein consisting of human RNase attached to the Fc portion of human IgG. The goal of the therapy is to reduce the burden of circulating RNA-containing immune complexes which are thought to be the most proximal trigger of the systemic inflammation characteristic of SLE. By eliminating the RNA cargo contained in circulating immune complexes the therapy is designed to prevent chronic activation of nucleic acid sensing toll like receptors (e.g. TLR7 and TLR8) and subsequent activation of the interferon inflammatory cascade. Additional therapeutic benefit is thought to result from dampening B-cell activation, as well as mitigation of the direct tissue damage caused by immune complex deposition in key organs, such as the kidney and brain.
"We are thrilled to move RSLV-132 one step closer to the large number of SLE patients that are not well controlled with current therapy" commented James Posada, chief executive officer of Resolve Therapeutics.
About Resolve Therapeutics
Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of its platform of targeted nuclease therapeutics. In addition to the lead molecule, RSLV-132, the company is developing additional molecules that contain both RNase and DNase activities, which may also be useful in the treatment of lupus and other autoimmune diseases resulting from aberrant nucleic acid deposition. Resolve is funded by a syndicate of venture capital firms including, New Science Ventures, WRF Capital, and Easton Capital. For more information on the company please visit us at: http://www.resolvebio.com.
James Posada, Ph.D., MBA
Chief Executive Officer
Resolve Therapeutics, LLC
©2012 PR Newswire. All Rights Reserved.